INTEGRA LIFESCIENCES HOLDINGS CORP 10-Q

ITEM 5. OTHER INFORMATION Rule 10b5-1 Trading Plans During the three months ended September 30, 2026, none of the Company’s directors or officers adopted or terminated any contract, instruction or written plan for the purchase or sale of Company securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) or any “non-Rule 10b5-1 trading arrangement.” ITEM 6. EXHIBITS Exhibits 3.1(a) Amended and Restated Certificate of Incorporation of the Company dated February 16, 1993 (Incorporated by reference to Exhibit 3.1(a) to the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2005) 3.1(b) Certificate of Amendment to Amended and Restated Certificate of Incorporation of the Company dated May 22, 1998 (Incorporated by reference to Exhibit 3.1(b) to the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 1998) 52 Table of Contents 3.1(c) Certificate of Amendment to Amended and Restated Certificate of Incorporation of the Company dated May 17, 1999 (Incorporated by reference to Exhibit 3.1(c) to the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2004) 3.1(d) Certificate of Amendment to Amended and Restated Certificate of Incorporation of the Company dated December 21, 2016 (Incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed on December 22, 2016) 3.1 (e) Certificate of Amendment to the Amended and Restated Certificate of Incorporation of the Company dated May 9, 2024 (Incorporated by reference to Exhibit 3.1(e) to the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 ) 3.2 Third Amended and Restated Bylaws of Integra LifeSciences Holdings Corporation, effective as of February 21, 2023 (Incorporated by reference to Exhibit 3.3 to the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022 filed on February 22, 2023) 4.1 Indenture, dated as of October 19, 2026, by and between Integra LifeSciences Holdings Corporation, Truist Bank, as trustee and notes collateral agent, and the guarantor parties thereto (Incorporated by reference to Exhibit 4.1 of the Company’s Current Report on Form 8-K filed on October 19, 2026) 10.1 Amended and Restated Credit Agreement, dated October 19, 2026, among Integra LifeSciences Holdings Corporation, the lenders party thereto, Bank of America, N.A., as Administrative Agent, Swing Line Lender and L/C Issuer, [JPMorgan Chase Bank, N.A., Citigroup Global Markets Inc., Citizens Bank, N.A., DNB Carnegie Inc., PNC Capital Markets LLC, Truist Securities, Inc., Capital One, National Association, Goldman Sachs Bank USA, Wells Fargo Securities, LLC, BMO Capital Markets Corp., Santander Bank, N.A., The Huntington National Bank, Morgan Stanley Senior Funding, Inc. and MUFG Bank, Ltd.], as Co-Syndication Agents, and The Bank of Nova Scotia and Pinnacle Bank, a Tennessee chartered bank, d/b/a Synovus Bank, as Co-Documentation Agents (Incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K filed on October 19, 2026) 10.2 Ratification Agreement, dated as of October 19, 2026, between Integra LifeSciences Holdings Corporation, the Subsidiary Guarantors of Integra LifeSciences Holdings Corporation and Bank of America, N.A., as Administrative Agent (Incorporated by reference to Exhibit 10.2 of the Company’s Current Report on Form 8-K filed on October 19, 2026) 10.3*+ Form of Integra LifeSciences Holdings Corporation Fifth Amended and Restated 2003 Equity Incentive Plan Restricted Stock Unit Award Agreement (2026) 10.4*+ Form of Integra LifeSciences Holdings Corporation Fifth Amended and Restated 2003 Equity Incentive Plan Non-Qualified Stock Option Award Agreement (2026) 31.1+ Certification of Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 31.2+ Certification of Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 32.1+ Certification of Principal Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 32.2+ Certification of Principal Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 101.INS+# Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. 101.SCH+# Inline XBRL Taxonomy Extension Schema Document 101.CAL+# Inline XBRL Taxonomy Extension Calculation Linkbase Document 101.DEF+# Inline XBRL Definition Linkbase Document 101.LAB+# Inline XBRL Taxonomy Extension Labels Linkbase Document 101.PRE+# Inline XBRL Taxonomy Extension Presentation Linkbase Document 104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) 53 Table of Contents 54 Table of Contents * Indicates a management contract or compensatory plan or arrangement. + Indicates this document is filed as an exhibit herewith. # The financial information of Integra LifeSciences Holdings Corporation Quarterly Report on Form 10-Q for the quarter ended September 30, 2026 filed on October 23, 2026 formatted in XBRL (Extensible Business Reporting Language): (i) the Condensed Consolidated Statements of Operations and Comprehensive Income, (ii) the Condensed Consolidated Balance Sheets, (iii) Parenthetical Data to the Condensed Consolidated Balance Sheets, (iv) the Condensed Consolidated Statements of Cash Flows, and (v) Notes to Condensed Consolidated Financial Statements, is furnished electronically herewith. 55 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. INTEGRA LIFESCIENCES HOLDINGS CORPORATION Date: October 23, 2026 /s/ Stuart M. Essig, Ph.D. Stuart M. Essig, Ph.D. Chairman, President and Chief Executive Officer (Principal Executive Officer) Date: October 23, 2026 /s/ Lea Knight Lea Knight Executive Vice President and Chief Financial Officer (Principal Financial Officer) Date: October 23, 2026 /s/ Jeffrey A. Mosebrook Jeffrey A. Mosebrook Senior Vice President, Finance (Principal Accounting Officer)